Loading...
•
Mar 31, 2022
Arrowhead Pharmaceuticals Q2 2022 Earnings Report
Reported fiscal 2022 second quarter results.
Key Takeaways
Arrowhead Pharmaceuticals reported a net income of $44.366 million and revenue of $151.805 million for the fiscal second quarter ended March 31, 2022.
Initiated the PALISADE Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome.
Completed enrollment of 204 patients in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for patients with mixed dyslipidemia.
Initiated the Phase 2 GATEWAY clinical study of ARO-ANG3 in patients with homozygous familial hypercholesterolemia (HoFH).
Initiated a Phase 1/2 study of ARO-C3 for various complement mediated diseases.
Forward Guidance
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...